Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.46 |
| ▸ | MEN1 | O00255 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | F2R | P25116 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818373 | 1.00 | MAPT (0.46) | MAPTMEN1KMT2AF2RL3LMNA | |
| SCHEMBL4823281 | 0.82 | MAPT (0.49) | MAPTMEN1KMT2AF2RL3LMNA | |
| SCHEMBL4823274 | 0.82 | MAPT (0.49) | MAPTMEN1KMT2AF2RL3LMNA | |
| SCHEMBL2846826 | 0.71 | VCAM1 (0.49) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL2846824 | 0.71 | VCAM1 (0.49) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL30600488 | 0.70 | MAPT (0.83) | MAPTMEN1KMT2AF2RL3LMNA | |
| SCHEMBL155568 | 0.70 | MAPT (0.83) | MAPTMEN1KMT2AF2RL3LMNA | |
| SCHEMBL17065022 | 0.70 | VCAM1 (0.51) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL17065023 | 0.70 | VCAM1 (0.51) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL13949744 | 0.67 | MEN1 (0.51) | MAPTMEN1KMT2ALMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465738-B2 | Compounds useful as promoters of SMN2 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-12-16 | — | — | US | disclosed |
| US-20050065173-A1 | Compounds useful as promoters of SMN2 | VERTEX PHARMACEUTICALS INCORPORATED | 2005-03-24 | — | — | US | disclosed |
| WO-2004113305-A2 | DIAMINO SUBSTITUTED QUINAZOLINE DERIVATIVES AS PROMOTERS OF SMN2 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065173-A1 | Compounds useful as promoters of SMN2 | SMN1; SMN2, NSUN2, MECP2 | MAPT 1001/4885MEN1 3565/4885KMT2A 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.